2. Academic Validation
  3. Fangchinoline induces gallbladder cancer cell apoptosis by suppressing PI3K/Akt/XIAP axis

Fangchinoline induces gallbladder cancer cell apoptosis by suppressing PI3K/Akt/XIAP axis

  • PLoS One. 2022 Apr 21;17(4):e0266738. doi: 10.1371/journal.pone.0266738.
Jiandong Li 1 2 3,  Wenda Cen 2 3 4,  Chenhao Tong 1 2 3,  Luna Wang 1 2 3,  Weiguang Zhang 5,  Shiqing Deng 2 3 4,  Jianhua Yu 2 3 4,  Baochun Lu 2 3 4
Affiliations

Affiliations

  • 1 Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
  • 2 Department of Hepatobiliary Surgery, Shaoxing People's Hospital (Shaoxing Hospital, Zhejiang University School of Medicine), Shaoxing, Zhejiang, China.
  • 3 Shaoxing Key Laboratory of Minimally Invasive Abdominal Surgery and Precise Treatment of Tumor, Shaoxing, Zhejiang, China.
  • 4 Shaoxing University Affiliated First Hospital, Shaoxing, Zhejiang, China.
  • 5 Department of Molecular Medicine and Clinical Laboratory, Shaoxing Second Hospital, Shaoxing, Zhejiang, China.
PMID: 35446864 DOI: 10.1371/journal.pone.0266738
Abstract

Gallbladder Cancer (GBC) is the most common biliary tract malignancy with a dismal prognosis. The development of new drugs may help to improve prognosis. This study found that fangchinoline, a Bisbenzylisoquinoline Alkaloids, inhibited the proliferation and clone formation of GBC cells in a dose-dependent manner. Moreover, Hoechst staining, TUNEL assays, and flow cytometry demonstrated that fangchinoline effectively induced Apoptosis in GBC cells. Further studies found that an anti-apoptotic pathway, the PI3K/Akt/XIAP axis, was significantly inhibited in GBC cells after treating with fangchinoline. Finally, we confirmed that fangchinoline restrained xenograft tumor growth in vivo. Our findings indicate that fangchinoline can be considered a potential drug for GBC treatment.

Figures
Products